Divi's Laboratories Limited is a Pharmaceuticals company listed on the National Stock Exchange (NSE) with a market capitalisation of ₹2.38 lakh crore. The company reports a net profit margin of 26%. Revenue grew +27.8% year-over-year. Promoter holding stands at 52%, with FII participation at 29.3%.
More buyers than usual are participating (volume expansion above average). Trading near its strongest price of the year (within 5% of 52-week high). Most stocks in the same industry are struggling (sector — most peers below EMA20). The uptrend is visible even on the weekly chart (longer-term trend confirmed). Even as price dipped, momentum is already recovering — a hidden strength signal (bullish RSI divergence). Results are due in 4–7 days — score reduced by 5 points; plan to exit before the announcement (earnings event risk). Price has pulled back to a natural support zone — a typical re-entry point in an uptrend (Fibonacci 23.6% retracement at ₹9,437). The overall market is in a downtrend — all trades carry higher risk right now (BEAR MARKET regime, reduced confidence). Above-average delivery percentage suggests real buying, not just speculation (delivery 68%). Price is right at the level where the most trading happened recently — strong support (Volume POC ₹9,327). Both short and medium-term trend lines are pointing upward — the trend has momentum (rising EMA20 + EMA50). Price is right at the ceiling of this year's range — a close above would be a significant breakout (at 52W high zone).
Divi's Laboratories Limited scores 48/100 (Mixed Research Signal). The strongest signals are Trend (14/100) and Volume Profile (10/100). The weakest dimension is Valuation (0/100), which warrants monitoring. This reflects JaySense quantitative research scoring only — not investment advice. Consult a SEBI Registered Investment Adviser before making any investment decision.